Search results
Showing 31 to 35 of 35 results for certolizumab pegol
This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough.
Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)
This guidance has been updated and replaced by NICE technology appraisal guidance 375.